Orchestra BioMed (NASDAQ: OBIO) net income
Orchestra BioMed reported a net loss of $52.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $61.0m. Earnings per share were −$1.11.
Orchestra BioMed's best year of the last 5 was fiscal 2021. It reported a loss in 5 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$52.7m | — | −157.4% | −$1.11 |
| 2024 | −$61.0m | — | −2,313.3% | −$1.66 |
| 2023 | −$49.1m | — | −1,779.7% | −$1.48 |
| 2022 | −$33.6m | — | −951.3% | −$2.24 |
| 2021 | −$0.4m | — | — | −$0.02 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Orchestra BioMed net income compared with its sector
By net income for its latest fiscal year, Orchestra BioMed ranks 262nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Orchestra BioMed, −157.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 260th | Invivyd | −$52.5m | −98.2% |
| 261st | Tenax Therapeutics | −$52.6m | — |
| 262nd | Orchestra BioMed | −$52.7m | −157.4% |
| 263rd | CVRX | −$53.3m | −94.1% |
| 264th | CeriBell | −$53.4m | −60.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Orchestra BioMed
- How much did Orchestra BioMed earn in fiscal 2025?
- Orchestra BioMed reported a net loss of $52.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $61.0m.
- What are the earnings per share of Orchestra BioMed?
- They were −$1.11 in fiscal 2025, compared with −$1.66 in fiscal 2024.
- Where does Orchestra BioMed rank in its sector by net income?
- It ranks 262nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Orchestra BioMed come from?
- From the annual report (Form 10-K) that Orchestra BioMed files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Orchestra BioMed files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Orchestra BioMed: the Orchestra BioMed page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.